The use of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been recommended in T2D to prevent progression of CKD in diabetes patients [52, 53] or even in patients without diabetes [54]. This evidence concerns the gene SLC5A2 and chronic kidney disease.